DE69624500D1 - Barbitursäure-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten - Google Patents

Barbitursäure-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten

Info

Publication number: DE69624500D1
Authority: DE; Germany
Prior art keywords: pct; group; monocycle; substituted; substituent selected
Prior art date: 1995-12-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69624500T

Other languages

English (en)

Other versions

DE69624500T2 (de

Inventor

Elmar Bosies

Angelika Esswein

Frank Grams

Hans-Willi Krell

Ernesto Menta

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Roche Diagnostics GmbH

Original Assignee

Roche Diagnostics GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-23

Filing date

1996-12-20

Publication date

2002-11-28

1996-12-20 Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH

1996-12-20 Priority to DE69624500T priority Critical patent/DE69624500T2/de

2002-11-28 Application granted granted Critical

2002-11-28 Publication of DE69624500D1 publication Critical patent/DE69624500D1/de

2003-07-17 Publication of DE69624500T2 publication Critical patent/DE69624500T2/de

2016-12-21 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000007656 barbituric acids Chemical class 0.000 title 1
239000008177 pharmaceutical agent Substances 0.000 title 1
-1 n-octyl Chemical group 0.000 abstract 4
125000001424 substituent group Chemical group 0.000 abstract 3
229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
125000004093 cyano group Chemical group *C#N 0.000 abstract 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
125000004193 piperazinyl group Chemical group 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
235000010290 biphenyl Nutrition 0.000 abstract 1
239000004305 biphenyl Substances 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
239000003475 metalloproteinase inhibitor Substances 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
125000005936 piperidyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/66—Thiobarbituric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DE69624500T 1995-12-23 1996-12-20 Barbitursäure-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten Expired - Fee Related DE69624500T2 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
DE69624500T DE69624500T2 (de)	1995-12-23	1996-12-20	Barbitursäure-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19548624A DE19548624A1 (de)	1995-12-23	1995-12-23	Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PCT/EP1996/005766 WO1997023465A1 (en)	1995-12-23	1996-12-20	New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
DE69624500T DE69624500T2 (de)	1995-12-23	1996-12-20	Barbitursäure-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten

Publications (2)

Publication Number	Publication Date
DE69624500D1 true DE69624500D1 (de)	2002-11-28
DE69624500T2 DE69624500T2 (de)	2003-07-17

Family

ID=7781338

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE19548624A Withdrawn DE19548624A1 (de)	1995-12-23	1995-12-23	Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69624500T Expired - Fee Related DE69624500T2 (de)	1995-12-23	1996-12-20	Barbitursäure-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE19548624A Withdrawn DE19548624A1 (de)	1995-12-23	1995-12-23	Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Country Status (22)

Country	Link
US (2)	US6110924A (de)
EP (1)	EP0869947B1 (de)
JP (1)	JP4198752B2 (de)
KR (1)	KR100440035B1 (de)
CN (1)	CN1318406C (de)
AT (1)	ATE226575T1 (de)
BR (1)	BR9612232A (de)
CZ (1)	CZ292503B6 (de)
DE (2)	DE19548624A1 (de)
DK (1)	DK0869947T3 (de)
ES (1)	ES2184903T3 (de)
HU (1)	HUP9901065A3 (de)
IL (1)	IL125048A (de)
MX (1)	MX9805063A (de)
NO (1)	NO311572B1 (de)
NZ (1)	NZ325802A (de)
PL (1)	PL190217B1 (de)
PT (1)	PT869947E (de)
RU (1)	RU2177475C2 (de)
TW (1)	TW518324B (de)
WO (1)	WO1997023465A1 (de)
ZA (1)	ZA9610765B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE302200T1 (de)	1997-06-21	2005-09-15	Roche Diagnostics Gmbh	Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
DE19726427A1 (de)	1997-06-23	1998-12-24	Boehringer Mannheim Gmbh	Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6350786B1 (en)	1998-09-22	2002-02-26	Hoffmann-La Roche Inc.	Stable complexes of poorly soluble compounds in ionic polymers
US6265578B1 (en) *	1999-02-12	2001-07-24	Hoffmann-La Roche Inc.	Pyrimidine-2,4,6-triones
PE20010659A1 (es)	1999-10-01	2001-06-20	Hoffmann La Roche	Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
AU2002210800A1 (en)	2000-10-26	2002-05-06	Pfizer Products Inc.	Pyrimidine-2,4,6-trione metalloproteinase inhibitors
US6716845B2 (en) *	2001-03-30	2004-04-06	Hoffmann-La Roche Inc.	Barbituric acid derivatives
WO2002089824A1 (en) *	2001-05-03	2002-11-14	F. Hoffmann-La Roche Ag	Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
CA2446356C (en)	2001-05-09	2012-07-10	The Regents Of The University Of Michigan	Use of compositions for treating rosacea
AU2002346729A1 (en) *	2001-12-20	2003-07-09	Bristol-Myers Squibb Company	Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
NI200300045A (es) *	2002-04-26	2005-07-08	Pfizer Prod Inc	Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
US20040225077A1 (en)	2002-12-30	2004-11-11	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
WO2004084903A1 (en) *	2003-03-27	2004-10-07	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) *	2003-03-28	2004-10-07	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment of chronic wounds
WO2004110457A1 (en) *	2003-06-06	2004-12-23	F. Hoffmann-La Roche Ag	Matrix metalloproteinases inhibitors for the stimulation and protection of bone marrow stem cells
EP1737464B1 (de) *	2004-04-01	2008-07-23	F. Hoffmann-La Roche AG	Verwendung von trioxopyrimidin zur behandlung und prävention von entzündlichen erkrankungen der bronchien
CN1950110B (zh)	2004-04-01	2012-11-21	列日大学	嘧啶-2,4,6-三酮的药物组合物
EP1632489A1 (de) *	2004-08-24	2006-03-08	University of Liege	5-(1,1'-Biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6-trione Derivate als Inhibitoren von Zink Metalloendopeptidasen, ihre Herstellung und Verwendung.
CN102234249B (zh) *	2010-04-23	2013-08-28	首都医科大学	N-(六氢嘧啶-1,3-二基)-二-l-氨基酸甲酯及其制备方法和应用
AU2011261375B2 (en)	2010-06-04	2016-09-22	Albany Molecular Research, Inc.	Glycine transporter-1 inhibitors, methods of making them, and uses thereof
KR101822417B1 (ko) *	2017-06-14	2018-01-29	주식회사 청도제약	인간의 체액에서 산화 스트레스를 측정하기 위한 방법
KR102432016B1 (ko)	2020-07-31	2022-08-16	부산대학교 산학협력단	신경염증질환 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2078323A (en) *		1937-04-27		C-amino-substituted barbituric
US2084136A (en) *	1933-06-03	1937-06-15	Heyden Chem Fab	Barbituric acid containing in the 5-position a pyridine group and method of preparing the same
DE763145C (de) *	1942-05-29	1954-05-03	Chem Fab Von Heyden A G	Verfahren zur Herstellung von 5-AEthyl-5-piperidinobarbitursaeure
US3930006A (en) *	1963-04-30	1975-12-30	Aspro Nicholas Ltd	Antiparkinsonism compositions and method
DE1246743B (de) *	1965-01-12	1967-08-10	Dresden Arzneimittel	Verfahren zur Herstellung von 5-Phenyl-5-piperidinobarbitursaeuren
DE19726427A1 (de) *	1997-06-23	1998-12-24	Boehringer Mannheim Gmbh	Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

1995
- 1995-12-23 DE DE19548624A patent/DE19548624A1/de not_active Withdrawn
1996
- 1996-12-20 BR BR9612232A patent/BR9612232A/pt not_active IP Right Cessation
- 1996-12-20 ZA ZA9610765A patent/ZA9610765B/xx unknown
- 1996-12-20 JP JP52331897A patent/JP4198752B2/ja not_active Expired - Fee Related
- 1996-12-20 PL PL96327466A patent/PL190217B1/pl not_active IP Right Cessation
- 1996-12-20 HU HU9901065A patent/HUP9901065A3/hu unknown
- 1996-12-20 CZ CZ19981968A patent/CZ292503B6/cs not_active IP Right Cessation
- 1996-12-20 CN CNB961800275A patent/CN1318406C/zh not_active Expired - Fee Related
- 1996-12-20 KR KR10-1998-0704855A patent/KR100440035B1/ko not_active IP Right Cessation
- 1996-12-20 PT PT96944612T patent/PT869947E/pt unknown
- 1996-12-20 DK DK96944612T patent/DK0869947T3/da active
- 1996-12-20 EP EP96944612A patent/EP0869947B1/de not_active Expired - Lifetime
- 1996-12-20 AT AT96944612T patent/ATE226575T1/de not_active IP Right Cessation
- 1996-12-20 US US09/091,352 patent/US6110924A/en not_active Expired - Fee Related
- 1996-12-20 WO PCT/EP1996/005766 patent/WO1997023465A1/en active IP Right Grant
- 1996-12-20 ES ES96944612T patent/ES2184903T3/es not_active Expired - Lifetime
- 1996-12-20 IL IL12504896A patent/IL125048A/en not_active IP Right Cessation
- 1996-12-20 NZ NZ325802A patent/NZ325802A/xx unknown
- 1996-12-20 RU RU98113916/04A patent/RU2177475C2/ru not_active IP Right Cessation
- 1996-12-20 DE DE69624500T patent/DE69624500T2/de not_active Expired - Fee Related
1997
- 1997-01-28 TW TW086101091A patent/TW518324B/zh not_active IP Right Cessation
1998
- 1998-06-22 MX MX9805063A patent/MX9805063A/es not_active IP Right Cessation
- 1998-06-22 NO NO19982901A patent/NO311572B1/no unknown
2000
- 2000-06-16 US US09/594,700 patent/US6472396B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6472396B1 (en)	2002-10-29
MX9805063A (es)	1998-10-31
KR100440035B1 (ko)	2004-09-18
PT869947E (pt)	2003-03-31
DK0869947T3 (da)	2003-02-24
HUP9901065A3 (en)	2001-10-29
ATE226575T1 (de)	2002-11-15
EP0869947A1 (de)	1998-10-14
CZ292503B6 (cs)	2003-10-15
ZA9610765B (en)	1998-07-17
DE69624500T2 (de)	2003-07-17
NO982901D0 (no)	1998-06-22
DE19548624A1 (de)	1997-06-26
CN1209123A (zh)	1999-02-24
US6110924A (en)	2000-08-29
HUP9901065A2 (hu)	1999-09-28
ES2184903T3 (es)	2003-04-16
EP0869947B1 (de)	2002-10-23
JP2000505069A (ja)	2000-04-25
NO311572B1 (no)	2001-12-10
TW518324B (en)	2003-01-21
CN1318406C (zh)	2007-05-30
NZ325802A (en)	2000-05-26
IL125048A (en)	2004-02-19
AU1303697A (en)	1997-07-17
IL125048A0 (en)	1999-01-26
BR9612232A (pt)	1999-07-13
AU722513B2 (en)	2000-08-03
WO1997023465A1 (en)	1997-07-03
PL190217B1 (pl)	2005-11-30
NO982901L (no)	1998-08-24
RU2177475C2 (ru)	2001-12-27
CZ196898A3 (cs)	1998-09-16
KR19990076734A (ko)	1999-10-15
PL327466A1 (en)	1998-12-07
JP4198752B2 (ja)	2008-12-17

Legal Events

Date	Code	Title	Description
2003-11-20	8364	No opposition during term of opposition
2010-10-21	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE69624500D1 (de)	2002-11-28	Barbitursäure-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten
DE69105131D1 (de)	1994-12-15	3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
GEP20033028B (en)	2003-07-25	Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof
ATE5258T1 (de)	1983-11-15	(piperidinylalkyl)chinazolin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
CY2509B1 (en)	2005-12-23	New thiazole derivatives with phosphodiesterase-inhibitting effect
ATE264107T1 (de)	2004-04-15	Cyclooxygenaseinhibitor und salze von amidinderivaten, verfahren zu deren herstellung, deren verwendung als arzneiwirkstoffe sowie diese salze enthaltende arzneimittel
ATE302778T1 (de)	2005-09-15	N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE264332T1 (de)	2004-04-15	Galanthamin-derivate, verfahren zu ihrer herstellung, ihre verwendung als arzmittel und diese enthaltende pharmazeutische zusammensetzung
DE59406279D1 (de)	1998-07-23	Neue harnstoffderivate, ihre herstellung und verwendung
ATE282615T1 (de)	2004-12-15	Neue beta-amyloid inhibitoren, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE69719511D1 (de)	2003-04-10	Antivirale 2,4-pyrimidindion-derivate und verfahren zu ihrer herstellung
DE69719974D1 (de)	2003-04-24	Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE161010T1 (de)	1997-12-15	Verwendung von cumarinen als pla 2-inhibitoren, neue cumarine, verfahren zu ihrer herstellung und arzneimittel
KR960703401A (ko)	1996-08-17	약학적 활성을 갖는 피리다지논 유도체[pyridazinone derivatives with pharmaceutical activity]
ATE214051T1 (de)	2002-03-15	Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
ATE288910T1 (de)	2005-02-15	Substituierte alkylaminopyridazinonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE60220779D1 (de)	2007-08-02	Tetrahydropyridyl-alkyl-heterozykle, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
DE59607683D1 (de)	2001-10-18	Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE60227506D1 (de)	2008-08-21	DIHYDROIMIDAZOi5,1-A -BETA-CARBOLIN-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE ANWENDUNG ALS ARZNEIMITTEL
ATE194357T1 (de)	2000-07-15	21-(2-oxo-tetrahydrofuran)-thio pregnan derivative, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon
DE59610387D1 (de)	2003-05-28	Phenanthridinderivate, verfahren zu ihrer herstellung und arzneimittel, enthaltend phenanthridinderivate
ATE207056T1 (de)	2001-11-15	Diphenylalkyl-tetrahydropyridine, verfahren zu ihren herstellung und diese enthaltende arzneimittel
ATE169925T1 (de)	1998-09-15	Pyrido 1,2,3-de>chinoxalinderivate, verfahren zu deren herstellung und ihre verwendung in arzneimitteln
DE60207895D1 (de)	2006-01-12	Neue piperidinylalkylaminopyridazinonderivate, ein verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese verbindungen enthalten
ATE240106T1 (de)	2003-05-15	Verfahren zur unterbrechung der desoxyribonukleotidtriphosphat-biosynthese